ArticlePLoS genetics2025
Genotype-phenotype characterization and functional reconstitution of pathogenic β-catenin variants from CTNNB1 syndrome patients.
Article in PLoS genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Harnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine.Stem cell research & therapy · 2026Review
- [Growth plate regulation and short stature: mechanistic insights and therapeutic advances].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germline variants in the CTNNB1 gene, encoding β-catenin protein, cause severe neurodevelopmental alterations manifested early in the infancy, and define the CTNNB1 syndrome. Patients with CTNNB1 syndrome display heterogeneous clinical manifestations, and most of them carry CTNNB1 pathogenic nonsense or frameshift variants that generate premature termination codons (PTC). We have previously described the neuropsychological manifestations of a group of CTNNB1 syndrome patients harboring novel β-catenin variants. Here, we have analysed the molecular and functional characterization of these β-catenin variants, performed genotype-phenotype analyses, and tested for β-catenin functional reconstitution. We describe a complex variety of N-terminal and C-terminal truncated β-catenin proteoforms generated by PTC. Protein stability of truncated proteoforms was variable, as indicated by their expression levels and biophysical analysis, and high protein stability correlated with better patient performance in visuospatial tests. Transcriptional activity was abrogated in most of the β-catenin variants, although some specific truncations, as well as a three-residues in-frame deletion variant, retained partial transcriptional activity. Reconstitution of full-length β-catenin expression and function was achieved in specific β-catenin PTC variants by induction of translational readthrough with aminoglycosides and protein synthesis stimulators. Inhibition of β-catenin degradation by MG-132 proteasome inhibitor also resulted in partial rescue of β-catenin transcriptional activity. Our results suggest the existence of intricate patterns of truncated β-catenin proteoforms in CTNNB1 syndrome patients, which may correlate with clinical manifestations, and provide insights to increase the function of β-catenin in patients carrying CTNNB1 pathogenic variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.